Literature DB >> 15614553

Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.

M Scholz1, C Engel, M Loeffler.   

Abstract

Cytotoxic drugs administered in polychemotherapy cause a characteristic neutropenic period depending on the schedule of the drugs, which can partly be prevented by G-CSF growth factor support. To quantify these effects and to gain a deeper insight into the dynamics of bone marrow recovery after such suppressing and stimulating disturbances, we construct a biomathematical compartment model of human granulopoiesis under polychemotherapy with G-CSF support. The underlying assumptions and mathematical techniques used to obtain the model are explained in detail. A large variety of biological and clinical data as well as knowledge from a model of murine haematopoiesis are evaluated to construct a physiological model for humans. Particular emphasis is placed on estimating the influence of chemotherapeutic drugs on the granulopoietic system. As a result, we present an innovative method to estimate the bone marrow damage caused by cytotoxic drugs with respect to single identifiable cell stages only on the basis of measured peripheral blood leukocyte dynamics. Conversely, our model can be used in a planning phase of a clinical trial to estimate the haematotoxicity of regimens based on new combinations of drugs already considered and with or without growth factor support.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15614553     DOI: 10.1007/s00285-004-0295-1

Source DB:  PubMed          Journal:  J Math Biol        ISSN: 0303-6812            Impact factor:   2.259


  35 in total

1.  The pharmacokinetics of [3H]-vincristine in man.

Authors:  R A Bender; M C Castle; D A Margileth; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

2.  Theoretical basis for cell cycle analysis: II. Further studies on labelled mitosis wave method.

Authors:  M Takahashi
Journal:  J Theor Biol       Date:  1968-02       Impact factor: 2.691

3.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.

Authors:  A P Grigg; A W Roberts; H Raunow; S Houghton; J E Layton; A W Boyd; K M McGrath; D Maher
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

Review 4.  Induction and regulation of endogenous granulocyte colony-stimulating factor formation.

Authors:  Lars Hareng; Thomas Hartung
Journal:  Biol Chem       Date:  2002-10       Impact factor: 3.915

5.  Model analysis of the contrasting effects of GM-CSF and G-CSF treatment on peripheral blood neutrophils observed in three patients with childhood-onset cyclic neutropenia.

Authors:  S Schmitz; H Franke; M Loeffler; H E Wichmann; V Diehl
Journal:  Br J Haematol       Date:  1996-12       Impact factor: 6.998

6.  Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Authors:  A Wunderlich; M Kloess; M Reiser; C Rudolph; L Truemper; S Bittner; H Schmalenberg; R Schmits; M Pfreundschuh; M Loeffler
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

7.  Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products.

Authors:  F Colotta; F Re; N Polentarutti; S Sozzani; A Mantovani
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

8.  The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans.

Authors:  M C Mackey; A A G Aprikyan; D C Dale
Journal:  Cell Prolif       Date:  2003-02       Impact factor: 6.831

9.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

10.  A mathematical model of erythropoiesis in mice and rats. Part 1: Structure of the model.

Authors:  M Loeffler; K Pantel; H Wulff; H E Wichmann
Journal:  Cell Tissue Kinet       Date:  1989-01
View more
  19 in total

1.  Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Authors:  Mélanie L Pastor; Céline M Laffont; Laurence Gladieff; Antonin Schmitt; Etienne Chatelut; Didier Concordet
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

2.  Modelling lymphoma therapy and outcome.

Authors:  Katja Roesch; Dirk Hasenclever; Markus Scholz
Journal:  Bull Math Biol       Date:  2013-12-14       Impact factor: 1.758

3.  The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling.

Authors:  T Stiehl; A D Ho; A Marciniak-Czochra
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

4.  Mathematical modeling of therapeutic strategies for myeloid malignancies.

Authors:  Dan Wu; Huiyu Li; Wen Du; Xiaoxia Ji; Wei Liu; Shiang Huang; Yi Xiao
Journal:  Pathol Oncol Res       Date:  2012-10       Impact factor: 3.201

5.  Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.

Authors:  M Scholz; C Engel; D Apt; S L Sankar; E Goldstein; M Loeffler
Journal:  Cell Prolif       Date:  2009-09-24       Impact factor: 6.831

6.  A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.

Authors:  M Scholz; M Ackermann; C Engel; F Emmrich; M Loeffler; M Kamprad
Journal:  Cell Prolif       Date:  2009-08-17       Impact factor: 6.831

Review 7.  Dynamic hematological disease: a review.

Authors:  Catherine Foley; Michael C Mackey
Journal:  J Math Biol       Date:  2008-03-04       Impact factor: 2.259

8.  Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.

Authors:  Markus Scholz; Manuela Ackermann; Frank Emmrich; Markus Loeffler; Manja Kamprad
Journal:  Biologics       Date:  2009-07-13

9.  Parameter identification of hematopoiesis mathematical model - periodic chronic myelogenous leukemia.

Authors:  Anahita Safarishahrbijari; Ali Gaffari
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15

10.  Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.

Authors:  Markus Scholz; Sibylle Schirm; Marcus Wetzler; Christoph Engel; Markus Loeffler
Journal:  Theor Biol Med Model       Date:  2012-07-30       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.